'We've Got The Jab, When Do We Deploy The Virus?'

H5N1 ‘Bird ‘Flu’. It’s a ‘spillover’ innit? A deadly ‘flu virus whose natural reservoir is not humans, but birds mainly, hens especially. We’re just waiting for it to ‘spill’ and start spreading dangerously through the human population. H5N1 definitely wasn’t created in a lab. Not like SARS-CoV-2. But, like SARS-CoV-2, the Pharma-Alchemists have a genetically modified Frankenvaccine ready and waiting to inject into as many arms as possible ‘just in case’ H5N1 makes the species leap from chicken to human. No, sorry, hen fanciers, it’s for humans only, so I’m afraid your backyard hens which you will be forced to register, even if you’ve only got one, will have to be culled ‘for the greater good’.

Peter McCullough on X:

Bird Flu vaccine has US Govt military BARDA fingerprints all over it. Self replicating RNA vaccine coming your way! Beware! Seqirus’ Adjuvanted, Cell-Based Technology AUDENZ™ combines Seqirus’ proprietary MF59® adjuvant technology with its cell-based manufacturing platform. Cell-based manufacturing, an alternative to traditional egg-based manufacturing, avoids egg-adapted changes, one source of strain mismatch between the vaccine and circulating influenza virus.5,6 Influenza vaccines using the MF59® adjuvant are designed to enhance and broaden the body’s immune response by creating broad, cross-reactive antibodies.7,8,9 This adjuvant is an important part of pandemic preparedness planning as it reduces the amount of antigen required to produce an immune response, increasing the number of doses of vaccine developed, so that a large number of people can be vaccinated as quickly as possible.10,11 Longstanding Partnership Between Seqirus and BARDA  Seqirus’ longstanding partnership with BARDA also supported the company’s cell-based manufacturing facility in Holly Springs, N.C., the first such domestic facility, that utilizes a highly scalable method of production. In October 2021, Seqirus announced a new $34.95 million agreement with BARDA to develop two influenza A(H2Nx) virus vaccine candidates: the first using the adjuvanted, cell-based combination platform technology used by AUDENZ™, and the second using Seqirus’ next-generation self-amplifying mRNA (sa-mRNA) platform. https://cslseqirus.us/news/fda-approves-multi-dose-vial-presentation-for-audenz…

Also Peter McCullough:

Could Avian H5N1 Influenza be Disease X for the Bio-Pharmaceutical Complex?

A few days ago, the CDC issued a health advisory for the H5N1 bird flu as it was detected in a Texas dairy farm worker [1]. His only symptom was conjunctivitis, or inflammation of the eye. As of today, human-to-human transmission has not occurred and thus H5N1 poses limited risk to humans. However, this may change in the near future, especially if we consider the dark history of gain of function (GOF) research regarding H5N1.

Which came first? The chicken or the egg? The ‘spillover’ Bird Flu virus (which I presume has developed some unique genetic mutation allowing it to infect humans and spread rapidly in humans thereafter, which mutation I presume the Pharma-Alchemists have amazingly anticipated in order to design their gene based vaccine) or the H5N1 vaccine?

Answers on the back of a Royal Mail postage stamp please.